-
1
-
-
0024452804
-
Design and analysis of phase I clinical trials
-
Storer BE: Design and analysis of phase I clinical trials. Biometrics 45: 925-937, 1989
-
(1989)
Biometrics
, vol.45
, pp. 925-937
-
-
Storer, B.E.1
-
2
-
-
0033966061
-
Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation
-
Roberts JD, Poplin EA, Tombes MB, Kyle B, Spicer DV, Grant S, Synold T, Moran R: Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation. Cancer Chemother Pharmacol 45: 103-110, 2000
-
(2000)
Cancer Chemother Pharmacol
, vol.45
, pp. 103-110
-
-
Roberts, J.D.1
Poplin, E.A.2
Tombes, M.B.3
Kyle, B.4
Spicer, D.V.5
Grant, S.6
Synold, T.7
Moran, R.8
-
3
-
-
0029808129
-
A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid
-
Laohavinij S, Wedge SR, Lind MJ, Bailey N, Humphreys A, Proctor M, Chapman F, Simmons D, Oakley A, Robson L, Gumbrell L, Taylor GA, Thomas HD, Boddy AV, Newell DR, Calvert AH: A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. Invest New Drug 14: 325-335, 1996
-
(1996)
Invest New Drug
, vol.14
, pp. 325-335
-
-
Laohavinij, S.1
Wedge, S.R.2
Lind, M.J.3
Bailey, N.4
Humphreys, A.5
Proctor, M.6
Chapman, F.7
Simmons, D.8
Oakley, A.9
Robson, L.10
Gumbrell, L.11
Taylor, G.A.12
Thomas, H.D.13
Boddy, A.V.14
Newell, D.R.15
Calvert, A.H.16
-
4
-
-
0031972610
-
Phase I trial of weekly paclitaxel in advanced lung cancer
-
Akerly W, Glantz M, Choy H, Rege V, Sambandam S, Joseph P, Yee L, Rodrigues B, Wingate P, Leone L: Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 16: 153-158, 1998
-
(1998)
J Clin Oncol
, vol.16
, pp. 153-158
-
-
Akerly, W.1
Glantz, M.2
Choy, H.3
Rege, V.4
Sambandam, S.5
Joseph, P.6
Yee, L.7
Rodrigues, B.8
Wingate, P.9
Leone, L.10
-
5
-
-
0028055206
-
Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer
-
Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C, Spriggs D: Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 12: 241-248, 1994
-
(1994)
J Clin Oncol
, vol.12
, pp. 241-248
-
-
Schiller, J.H.1
Storer, B.2
Tutsch, K.3
Arzoomanian, R.4
Alberti, D.5
Feierabend, C.6
Spriggs, D.7
-
6
-
-
8944245005
-
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
-
Nabholtz J-M, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winegrad B: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14: 1858-867, 1996
-
(1996)
J Clin Oncol
, vol.14
, pp. 1858-1867
-
-
Nabholtz, J.-M.1
Gelmon, K.2
Bontenbal, M.3
Spielmann, M.4
Catimel, G.5
Conte, P.6
Klaassen, U.7
Namer, M.8
Bonneterre, J.9
Fumoleau, P.10
Winegrad, B.11
-
7
-
-
0003098321
-
Alkylating agents
-
Chabner BA, Longo DL (eds). Lippincott-Raven, Philadelphia
-
Tew K, Colvin M, Chabner BA: Alkylating agents. In: Chabner BA, Longo DL (eds) Cancer Chemotherapy and Biotherapy: Principles and Practice. Lippincott-Raven, Philadelphia, 1996, pp 297-332
-
(1996)
Cancer Chemotherapy and Biotherapy: Principles and Practice
, pp. 297-332
-
-
Tew, K.1
Colvin, M.2
Chabner, B.A.3
-
9
-
-
0025148278
-
Continual reassessment method: A practical design for Phase I clinical studies in cancer
-
O'Quigley J, Pepe M, Fisher L: Continual reassessment method: a practical design for Phase I clinical studies in cancer. Biometrics 46: 33-48, 1990
-
(1990)
Biometrics
, vol.46
, pp. 33-48
-
-
O'Quigley, J.1
Pepe, M.2
Fisher, L.3
-
10
-
-
0028849683
-
Initial Phase I evaluation of the novel thymidylate sythase inhibitor, LY231514, using the modified continual reassessment method for dose escalation
-
Rinaldi DA, Burris HA, Dorr FA, Woodworth JR, Kuhn JG, Ecardt JR, Rodriguez G, Corso SW, Fields SM, Langley C, Clark G, Faries D, Lu P, Von Hoff DD: Initial Phase I evaluation of the novel thymidylate sythase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 13: 2842-2850, 1995.
-
(1995)
J Clin Oncol
, vol.13
, pp. 2842-2850
-
-
Rinaldi, D.A.1
Burris, H.A.2
Dorr, F.A.3
Woodworth, J.R.4
Kuhn, J.G.5
Ecardt, J.R.6
Rodriguez, G.7
Corso, S.W.8
Fields, S.M.9
Langley, C.10
Clark, G.11
Faries, D.12
Lu, P.13
Von Hoff, D.D.14
-
11
-
-
0028060511
-
Practical modification of the continual reassessment method for phase I cancer clinical trials
-
Faries D: Practical modification of the continual reassessment method for phase I cancer clinical trials. J Biopharm Stat 4: 147-164, 1994
-
(1994)
J Biopharm Stat
, vol.4
, pp. 147-164
-
-
Faries, D.1
-
12
-
-
0035300677
-
Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer
-
Ewesuedo, RB, Iyer L, Das S, Koenig A, Mani S, Vogelzang NJ, Schilsky RL, Brenckman W, Ratain MJ: Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer. J Clin Oncol 19: 2084-2090, 2001
-
(2001)
J Clin Oncol
, vol.19
, pp. 2084-2090
-
-
Ewesuedo, R.B.1
Iyer, L.2
Das, S.3
Koenig, A.4
Mani, S.5
Vogelzang, N.J.6
Schilsky, R.L.7
Brenckman, W.8
Ratain, M.J.9
-
13
-
-
0031036177
-
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer
-
Fennelly D, Aghajanian C, Shapiro F, O'Flaherty C, McKenzie M, O'Connor C, Tong W, Norton L, Spriggs D: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 15: 187-192, 1997
-
(1997)
J Clin Oncol
, vol.15
, pp. 187-192
-
-
Fennelly, D.1
Aghajanian, C.2
Shapiro, F.3
O'Flaherty, C.4
McKenzie, M.5
O'Connor, C.6
Tong, W.7
Norton, L.8
Spriggs, D.9
-
14
-
-
0031025090
-
Maximum-tolerated dose defined for single-agent gemcitabine: A phase I dose-escalation study in chemotherapy-naïve patients with advanced non-small-cell lung cancer
-
Fosella FV, Lippman S, Shin DM, Tarassoff P, Calayag-Jung M, Perez-Soler R, Lee JS, Murphy WK, Glisson B, Rivera E, Hong WK: Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naïve patients with advanced non-small-cell lung cancer. J Clin Oncol 15: 310-316, 1997
-
(1997)
J Clin Oncol
, vol.15
, pp. 310-316
-
-
Fosella, F.V.1
Lippman, S.2
Shin, D.M.3
Tarassoff, P.4
Calayag-Jung, M.5
Perez-Soler, R.6
Lee, J.S.7
Murphy, W.K.8
Glisson, B.9
Rivera, E.10
Hong, W.K.11
-
15
-
-
0027140524
-
Phase I and pharmacokinetic trial of weekly CPT-11
-
Rothenberg ML, Kuhn JG, Burris HA, Nelson J, Eckard JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI, Rock MK, Von Hoff DD: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11: 2194-2204, 1993
-
(1993)
J Clin Oncol
, vol.11
, pp. 2194-2204
-
-
Rothenberg, M.L.1
Kuhn, J.G.2
Burris, H.A.3
Nelson, J.4
Eckard, J.R.5
Tristan-Morales, M.6
Hilsenbeck, S.G.7
Weiss, G.R.8
Smith, L.S.9
Rodriguez, G.I.10
Rock, M.K.11
Von Hoff, D.D.12
-
16
-
-
0027715143
-
Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies
-
Schiller JH, Storer B, Arzoomanian R, Tutsch K, Alberti D, Spriggs D: Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies. Invest New Drugs 11: 291-300, 1993
-
(1993)
Invest New Drugs
, vol.11
, pp. 291-300
-
-
Schiller, J.H.1
Storer, B.2
Arzoomanian, R.3
Tutsch, K.4
Alberti, D.5
Spriggs, D.6
-
17
-
-
0028291647
-
Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis
-
Tomiak E, Piccart MJ, Kerger J, Lips S, Awada A, de Valeriola D, Ravoet C, Lossignol D, Sculier P, Auzannet V, Le Bail N, Bayssas M, Klastersky J: Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 12: 1458-1467, 1994.
-
(1994)
J Clin Oncol
, vol.12
, pp. 1458-1467
-
-
Tomiak, E.1
Piccart, M.J.2
Kerger, J.3
Lips, S.4
Awada, A.5
De Valeriola, D.6
Ravoet, C.7
Lossignol, D.8
Sculier, P.9
Auzannet, V.10
Le Bail, N.11
Bayssas, M.12
Klastersky, J.13
-
18
-
-
0027933519
-
Phase I and phannacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients
-
DeForni M, Bugat R, Chabot GG, Culine S, Extra JM, Gouyette A, Madelaine I, Marty ME, Mathieu-Boue A: Phase I and phannacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54: 4347-4354, 1994
-
(1994)
Cancer Res
, vol.54
, pp. 4347-4354
-
-
DeForni, M.1
Bugat, R.2
Chabot, G.G.3
Culine, S.4
Extra, J.M.5
Gouyette, A.6
Madelaine, I.7
Marty, M.E.8
Mathieu-Boue, A.9
-
19
-
-
0010267346
-
Phase I/pharmacokinetic study of topotecan by 24 hour continuous infusion weekly
-
Haas NB, LaCreta FP, Walczak J, Hudes GR, Brennan JM, Ozols RF, O'Dwyer J: Phase I/pharmacokinetic study of topotecan by 24 hour continuous infusion weekly. Cancer Res 54: 1220-1226, 1994
-
(1994)
Cancer Res
, vol.54
, pp. 1220-1226
-
-
Haas, N.B.1
LaCreta, F.P.2
Walczak, J.3
Hudes, G.R.4
Brennan, J.M.5
Ozols, R.F.6
O'Dwyer, J.7
-
20
-
-
0029963324
-
Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: Usefulness of mathematical modeling to determine maximum-tolerable dose
-
Shepherd FA, Burkes R, Cormier Y, Crump M, Feld R, Strack T, Schulz M: Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematical modeling to determine maximum-tolerable dose. J Clin Oncol 14: 1656-1662, 1996
-
(1996)
J Clin Oncol
, vol.14
, pp. 1656-1662
-
-
Shepherd, F.A.1
Burkes, R.2
Cormier, Y.3
Crump, M.4
Feld, R.5
Strack, T.6
Schulz, M.7
-
21
-
-
0030749549
-
Accelerated titration designs for phase I clinical trials in oncology
-
Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC: Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89: 1138-1147, 1997
-
(1997)
J Natl Cancer Inst
, vol.89
, pp. 1138-1147
-
-
Simon, R.1
Freidlin, B.2
Rubinstein, L.3
Arbuck, S.G.4
Collins, J.5
Christian, M.C.6
-
22
-
-
0022569778
-
Potential roles for preclinical pharmacology in phase I clinical trials
-
Collins JM, Zaharko DS, Dedrick RL, Chabner BA: Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 70: 73-80, 1986
-
(1986)
Cancer Treat Rep
, vol.70
, pp. 73-80
-
-
Collins, J.M.1
Zaharko, D.S.2
Dedrick, R.L.3
Chabner, B.A.4
-
23
-
-
0027499297
-
Model-guided determination of maximum tolerated dose in phase I clinical trials: Evidence for increased precision
-
Mick R, Ratain MJ: Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision. J Natl Cancer Inst 85: 217-223, 1993
-
(1993)
J Natl Cancer Inst
, vol.85
, pp. 217-223
-
-
Mick, R.1
Ratain, M.J.2
|